“We are proud to bring gammaCore to the U.S. market, as it provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition,” said Francis R. Amato, Chief Executive Officer of electroCore. “The commercial launch also signifies an important milestone for electroCore, marking the first marketed product for the company in the U.S.”
Patients can receive the device by enrolling in gammaCore Patient Registry (GPR), a non-research registry intended to examine the patient experience with gammaCore. As part of the registry, those eligible may receive two months of gammaCore treatment at no cost to the patient, in return for sharing information about their experience with the device along with periodic quality-of-life, self-reported outcomes. Additional key offerings of GPR include:
- An interactive, online tracker to record information about cluster attacks as they occur
- Hands-on training for how to use gammaCore from a GPR coordinator
- Access to online and in-person support from a care specialist throughout the duration of treatment
- Co-pay assistance for up to one year